Premium
Topiramate treatment in bulimia nervosa patients: A randomized, double‐blind, placebo‐controlled trial
Author(s) -
Nickel Cerstin,
Tritt Karin,
Muehlbacher Moritz,
Pedrosa Gil Francisco,
Mitterlehner Ferdinand O.,
Kaplan Patrick,
Lahmann Claas,
Leiberich Peter K.,
Krawczyk Jakub,
Kettler Christian,
Rother Wolfhardt K.,
Loew Thomas H.,
Nickel Marius K.
Publication year - 2005
Publication title -
international journal of eating disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.785
H-Index - 138
eISSN - 1098-108X
pISSN - 0276-3478
DOI - 10.1002/eat.20202
Subject(s) - topiramate , placebo , weight loss , bulimia nervosa , randomized controlled trial , psychology , confidence interval , medicine , anesthesia , psychiatry , eating disorders , obesity , epilepsy , alternative medicine , pathology
Objective The aim of the current study was to test the influence of topiramate on behavior, body weight, and health‐related quality of life (HRQOL) in bulimic patients. Method Thirty patients with bulimia nervosa were treated with topiramate in a 10‐week randomized, double‐blind, placebo‐controlled study. The subjects were randomly assigned to receive topiramate (topiramate group [TG]; n = 30) or a placebo (control group [CG]; n = 30). Primary outcome measures were changes in the frequency of binging/purging, in body weight, and on the SF‐36 Health Survey (SF‐36) scales. Results In comparison to the CG group (according to the intent‐to‐treat principle), significant changes in the frequency of binging/purging (a > 50% reduction: TG, n = 11 [36.7%]; CG, n = 1 [3.3%]; p < .001), body weight (difference in weight loss between the two groups: 3.8 kg, 95% confidence interval [CI] = −5.4 to −2.1; p < .001), and SF‐36 (all p s < .001) could be seen. All patients tolerated topiramate well. Conclusion Topiramate appears to safe and effective in influencing the frequency of binging/purging, body weight, and HRQOL in bulimic patients. © 2005 by Wiley Periodicals, Inc.